<?xml version="1.0" encoding="UTF-8"?>
<ref id="B33-pharmaceutics-11-00040" class="ref">
 <label class="label">33.</label>
 <element-citation publication-type="journal" class="element-citation">
  <person-group person-group-type="author" class="person-group">
   <name class="name">
    <surname class="surname">Genedy</surname>
    <given-names class="given-names">S.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Khames</surname>
    <given-names class="given-names">A.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Hussein</surname>
    <given-names class="given-names">A.</given-names>
   </name>
   <name class="name">
    <surname class="surname">Sarhan</surname>
    <given-names class="given-names">H.</given-names>
   </name>
  </person-group>
  <article-title class="article-title">Hydralazine HCl rapidly disintegrating sublingual tablets: Simple dosage form of higher bioavailability and enhanced clinical efficacy for potential rapid control on hypertensive preeclampsia</article-title>
  <source class="source">Drug Des. Dev. Ther.</source>
  <year class="year">2018</year>
  <volume class="volume">12</volume>
  <fpage class="fpage">3753</fpage>
  <lpage class="lpage">3766</lpage>
  <pub-id pub-id-type="doi" class="pub-id">10.2147/DDDT.S173326</pub-id>
 </element-citation>
</ref>
